Search results
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Digital Journal· 16 hours agoMarlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing ...